Purpose Patient-reported outcomes including health-related quality of life (HRQoL) are
important oncological outcome measures. The validation of HRQoL instruments for patients …

Purpose Advanced hepatocellular carcinoma (HCC) not eligible for local therapies has
limited chances of cure. Sorafenib is a multikinase inhibitor with proven activity in advanced …

Background Hepatocellular (HCC) and cholangiocellular carcinomas (CCC) display an
exceptionally poor prognosis. Especially for advanced disease no efficient standard therapy …

Pseudoacromegaly encompasses a heterogeneous group of conditions in which patients
have clinical features of acromegaly or gigantism, but no excess of GH or IGF-1 …

Aim: This study was designed to evaluate the effects of dietary and lifestyle habits on several
blood lipid parameters in the Lebanese population. Methods: This was a cross-sectional …

Liver resections for hepatocellular carcinoma (HCC) in cirrhotic livers are associated with
early recurrence and poor survival. Somatostatin analogues (SSAs) have been reported to …

Objective Advanced hepatocellular cancer (HCC) is a highly vascularised tumor with limited
treament options. We wanted to evaluate the impact of different treatments on systemic …

The neuropeptide somatostatin has been shown to control the secretion of several
hormones and growth factors, but also to inhibit the proliferation of several tumor cells …

The treatment of advanced hepatocellular carcinoma (HCC) in patients no longer eligible for
surgical, percutaneous or transarterial therapies is dismal. Chemotherapy, anti-estrogens or …

1 Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;
9: 669e676. 2Giantonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab in …